MT2021-27 FT538 Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer

NCT05708924 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

1

Enrollment

OTHER

Sponsor class

Stopped Product withdrawn from clinical development

Conditions

Cancer
Solid Tumor
Ovarian Cancer
Peritoneal Cancer
Fallopian Tube Cancer

Interventions

DRUG: FT538
BIOLOGICAL: Enoblituzumab

Sponsor

Masonic Cancer Center, University of Minnesota

Collaborators

[object Object]